CN112999096A - Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof - Google Patents
Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof Download PDFInfo
- Publication number
- CN112999096A CN112999096A CN202110352307.8A CN202110352307A CN112999096A CN 112999096 A CN112999096 A CN 112999096A CN 202110352307 A CN202110352307 A CN 202110352307A CN 112999096 A CN112999096 A CN 112999096A
- Authority
- CN
- China
- Prior art keywords
- freeze
- active polypeptide
- sponge
- drying
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 82
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 75
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 43
- 108010035532 Collagen Proteins 0.000 claims abstract description 43
- 229920001436 collagen Polymers 0.000 claims abstract description 43
- 238000004108 freeze drying Methods 0.000 claims abstract description 40
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 38
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 38
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 38
- 229920001661 Chitosan Polymers 0.000 claims abstract description 32
- 239000007788 liquid Substances 0.000 claims abstract description 31
- 239000000047 product Substances 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003223 protective agent Substances 0.000 claims abstract description 24
- 239000010413 mother solution Substances 0.000 claims abstract description 22
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 14
- 239000006174 pH buffer Substances 0.000 claims abstract description 12
- 239000012265 solid product Substances 0.000 claims abstract description 6
- 238000005516 engineering process Methods 0.000 claims abstract description 4
- 238000012545 processing Methods 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims description 39
- 238000007710 freezing Methods 0.000 claims description 28
- 230000008014 freezing Effects 0.000 claims description 28
- 230000001954 sterilising effect Effects 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000006179 pH buffering agent Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 19
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 19
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 19
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 13
- 229930182555 Penicillin Natural products 0.000 claims description 12
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 12
- 229940049954 penicillin Drugs 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 6
- 108010087806 Carnosine Proteins 0.000 claims description 6
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 6
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 6
- 229940044199 carnosine Drugs 0.000 claims description 6
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 4
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 239000002574 poison Substances 0.000 claims description 4
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 108010036176 Melitten Proteins 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims description 3
- 241000239226 Scorpiones Species 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 21
- 239000012452 mother liquor Substances 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 238000005086 pumping Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011049 filling Methods 0.000 description 4
- 229920000832 Cutin Polymers 0.000 description 3
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002795 scorpion venom Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- -1 conopeptide Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a cosmetic product freeze-dried sponge containing active polypeptide and a preparation method thereof. The freeze-dried sponge refers to a sponge-like tissue solid product obtained by processing a mother solution prepared according to a formula by a vacuum freeze-drying technology. The liquid preparation formula of the freeze-dried sponge comprises 0.01-1.0% of active polypeptide, 0.01-1.0% of sodium hyaluronate, 0.01-1.0% of recombinant human collagen, 0.5-3.0% of chitosan, 0.1-1.0% of protein protective agent, 0.1-2.0% of pH buffer agent and 91.0% -99.27% of water by weight. Compared with the conventional freeze-drying sponge, the freeze-drying sponge has the advantages of more loose structure, higher moisture absorption and retention functions and capability of being formed with less solute. The invention uses the recombinant human collagen, the active polypeptide, the sodium hyaluronate and the chitosan in a reasonable proportion, and well achieves the effect of skin.
Description
The technical field is as follows:
the invention relates to the technical field of beauty products, in particular to a freeze-dried sponge containing active polypeptide for beauty products and a preparation method thereof.
Background art:
the freeze-dried sponge is a sponge-like tissue solid product formed by vacuum freeze drying, and compared with the conventional freeze-dried sponge, the freeze-dried sponge has the advantages of more loose structure, higher moisture absorption and retention functions and capability of being formed with less solute.
The polypeptide is a compound formed by connecting alpha-amino acids together by peptide bonds, and the compound formed by dehydration condensation of three or more amino acid molecules can be called as active polypeptide, is an important physiological regulator for human bodies, can comprehensively regulate the physiological functions of the human bodies, enhances and exerts the physiological activity of the human bodies, and has important biological functions.
The recombinant human collagen is produced in gene engineering mode and has similarity to human collagen sequence up to 100%. The recombinant human collagen has a remarkable promoting effect on cell migration, has the effects of repairing cutin and maintaining the integrity of the cutin, and has the promoting effects on the differentiation of the cutin cells, the maintenance of the normal functions of the skin and the renewal of the skin.
At present, the existing collagen freeze-dried sponges and chitosan freeze-dried sponges are mainly applied to the medical wound repair direction, the application case of the freeze-dried sponges of the active polypeptide cosmetic products in the cosmetic products is not available, and the active polypeptide cosmetic products mainly appear in the forms of liquid, jelly, cream and freeze-dried sponges, and are limited by dosage forms, so that more auxiliary substances (film forming agents, preservatives and the like) are required to be added to achieve the effect, unnecessary safety risks are increased, and the application of the freeze-dried sponges in the cosmetic products is a problem to be solved urgently.
The invention content is as follows:
in order to achieve the aim, the invention provides the freeze-dried sponge containing the active polypeptide cosmetic product, which gives consideration to repair and bacteriostasis well, and solves the problem of tissue seepage of wounds and provides a breathable comfortable effect due to the loose sponge structure and water absorption. The sponge-like tissue solid product is characterized in that the freeze-dried sponge refers to a sponge-like tissue solid product obtained by processing a liquid (mother liquor) prepared according to a formula through a vacuum freeze-drying technology, the liquid preparation formula of the freeze-dried sponge comprises 0.01-1.0% of active polypeptide, 0.01-1.0% of sodium hyaluronate, 0.01-1.0% of recombinant human collagen, 0.5-3.0% of chitosan, 0.1-1.0% of protein protective agent, 0.1-2.0% of pH buffer and 91.0-99.27% of water by weight percent;
further, the active polypeptide in the liquid preparation formula of the freeze-dried sponge is one or more of acetyl hexapeptide-8, snake-like venom peptide, nonapeptide-1, tripeptide-1, melittin, scorpion venom peptide, conopeptide, carnosine and the like (including but not limited to the following active polypeptides), and the mass percentages of the active polypeptides are as follows: 0.01 to 1.0 percent;
further, the sodium hyaluronate in the liquid preparation formula of the freeze-dried sponge is small-molecule sodium hyaluronate (about 10000Da) and the mass percentage is as follows: 0.01 to 1.0 percent
Further, the recombinant human collagen in the liquid preparation formula of the freeze-dried sponge is recombinant human collagen III, and the liquid preparation formula of the freeze-dried sponge comprises the following components in percentage by mass: 0.01 to 1.0 percent;
further, chitosan in the liquid preparation formula of the freeze-dried sponge is carboxymethyl chitosan, and the weight percentage of the chitosan is as follows: 0.5 to 3.0 percent;
further, the protein protective agent in the liquid preparation formula of the freeze-dried sponge is mannitol, and the freeze-dried sponge comprises the following components in percentage by mass: 0.1 to 1.0 percent;
further, the pH buffering agent comprises disodium hydrogen phosphate and sodium dihydrogen phosphate, wherein the weight percentage of the disodium hydrogen phosphate: 0.05-1.0%, sodium dihydrogen phosphate: 0.05-1.0 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 200-500 rpm for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the active polypeptide and the sodium hyaluronate, and stirring at 200-500 rpm for complete dissolution to obtain a mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
Further, the sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooling to less than or equal to 40 ℃.
Further, the temperature of adding the recombinant human collagen, the active polypeptide and the sodium hyaluronate in the step S2 is less than or equal to 40 ℃.
Further, in the step S3, the freeze-drying step includes pre-freezing, vacuum-pumping, temperature-raising, primary drying, and resolution drying in sequence.
Further, the freeze drying specifically comprises: setting the temperature of a plate layer to be-40 to-30 ℃, and pre-freezing for 1 to 3 hours; after pre-freezing, when the temperature of the rear box reaches-50 to-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.6 to 0.8mbar, heating is started; in the primary drying stage, firstly setting the temperature of a plate layer to be-20 to-10 ℃ for 5 to 8 hours, and then setting the temperature of the plate layer to be-5 to 5 ℃ for 1 to 3 hours; and in the analysis and drying stage, setting the temperature of the plate layer to be 8-15 ℃ and the duration to be 1-3 h, and then setting the temperature of the plate layer to be 20-40 ℃ and continuing for 2-5 h.
The invention has the beneficial effects that:
compared with the conventional freeze-drying sponge, the freeze-drying sponge has the advantages of more loose structure, higher moisture absorption and retention functions and capability of being formed with less solute.
The invention uses the recombinant human collagen, the active polypeptide, the sodium hyaluronate and the carboxymethyl chitosan in a reasonable proportion, and well achieves the effect of nursing the skin.
The invention adopts a freeze-drying form, and the production process is in vacuum and low temperature, and the water content of the finished product is extremely low, so that the traditional conditions of excessive additives and loss of activity are avoided, the product stability is good, and the risk of adverse reaction of the product is reduced.
The specific implementation mode is as follows:
the freeze-dried sponge according to the present invention will be explained below.
The freeze-dried sponge of the invention refers to a sponge-like tissue solid product obtained by processing liquid (mother liquor) prepared according to a formula by a vacuum freeze-drying technology.
The preparation formula of the liquid (mother liquor) of the freeze-dried sponge comprises active polypeptide, sodium hyaluronate, recombinant human collagen, chitosan, a protein protective agent, a pH buffering agent and water. According to weight percentage, 0.01 to 1.0 percent of active polypeptide, 0.01 to 1.0 percent of sodium hyaluronate, 0.01 to 1.0 percent of recombinant human collagen, 0.5 to 3.0 percent of chitosan, 0.1 to 1.0 percent of protein protective agent, 0.1 to 2.0 percent of pH buffer agent and 91.0 to 99.27 percent of water;
the active polypeptide is one or more of acetyl hexapeptide-8, snake-like poison peptide, nonapeptide-1, tripeptide-1, melittin, scorpion poison peptide, conopeptide, carnosine and the like, and the mass percent is as follows: 0.01 to 1.0 percent; (the percentages are based on the total amount of lyophilized sponge liquid (mother liquor) before lyophilization)
The sodium hyaluronate is small molecular sodium hyaluronate (about 10000Da) and comprises the following components in percentage by mass: 0.01 to 1.0 percent; (the percentages are based on the total amount of lyophilized sponge liquid (mother liquor) before lyophilization)
The recombinant human collagen is recombinant human type III collagen and comprises the following components in percentage by mass: 0.01 to 1.0 percent; (the percentages are based on the total amount of lyophilized sponge liquid (mother liquor) before lyophilization)
The chitosan is carboxymethyl chitosan, and comprises the following components in percentage by mass: 0.5 to 3.0 percent; (the percentages are based on the total amount of lyophilized sponge liquid before lyophilization)
The protein protective agent is mannitol and comprises the following components in percentage by mass: 0.1 to 1.0 percent; (the percentages are based on the total amount of lyophilized sponge liquid before lyophilization)
The pH buffering agent comprises disodium hydrogen phosphate and sodium dihydrogen phosphate, wherein the weight percentage of the disodium hydrogen phosphate is as follows: 0.05-1.0%, sodium dihydrogen phosphate: 0.05-1.0 percent. (the percentages are based on the total amount of lyophilized sponge liquid before lyophilization)
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 200-500 rpm for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the active polypeptide and the sodium hyaluronate, and stirring at 200-500 rpm for complete dissolution to obtain a mother solution;
the sterilization in the step specifically comprises the following steps: sterilizing the mixture at 121 deg.C with high temperature steam for 15 min. Cooling to a temperature of less than or equal to 40 ℃ after sterilization.
It is noted that the temperature for adding the recombinant human collagen, the active polypeptide and the sodium hyaluronate is less than or equal to 40 ℃.
S3, filling the mother solution into penicillin bottles (the specification of the invention is 3 ml), filling the penicillin bottles with the liquid filling amount of 1.1ml, and performing freeze drying on the penicillin bottles in a vacuum freeze dryer (the model is GLZY-20B) after half filling to obtain the freeze-dried sponge.
In the step, the step of freeze drying is prefreezing- > vacuumizing- > heating- > primary drying- > resolving and drying.
Further, the freeze drying specifically comprises: setting the temperature of a plate layer to be-40 to-30 ℃ by using a vacuum freeze dryer (the model is GLZY-20B), and pre-freezing for 1 to 3 hours; after pre-freezing, when the temperature of the rear box reaches-50 to-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.6 to 0.8mbar, heating is started; in the primary drying stage, firstly setting the temperature of a plate layer to be-20 to-10 ℃ for 5 to 8 hours, and then setting the temperature of the plate layer to be-5 to 5 ℃ for 1 to 3 hours; and in the analysis and drying stage, setting the temperature of the plate layer to be 8-15 ℃ and the duration to be 1-3 h, and then setting the temperature of the plate layer to be 20-40 ℃ and continuing for 2-5 h.
The following examples are further illustrative of the present invention and are not intended to be limiting thereof.
Example 1:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.02% of active polypeptide, 0.6% of sodium hyaluronate, 0.8% of chitosan, 0.5% of protein protective agent, 0.5% of pH buffer, 96.58% of water and 1% of recombinant human collagen;
the active polypeptide is acetyl hexapeptide-8;
in the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 0.25%, sodium dihydrogen phosphate: 0.25 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 5 ℃.
In the step of S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 5 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
The freeze drying specifically comprises: setting the temperature of the plate layer to be 40 ℃ below zero, and pre-freezing for 1 h; after pre-freezing, when the temperature of the rear box reaches-50 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.6mbar, heating is started; in the primary drying stage, firstly setting the temperature of the plate layer to be 20 ℃ below zero for 5 hours, and then setting the temperature of the plate layer to be 5 ℃ below zero for 1 hour; and in the analysis and drying stage, the temperature of the plate layer is set to be 8 ℃, the duration time is 1h, and the temperature of the plate layer is set to be 20 ℃ again and the duration time is 2 h.
Example 2:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.03% of active polypeptide, 0.2% of sodium hyaluronate, 0.5% of chitosan, 0.7% of protein protective agent, 0.5% of pH buffer agent, 97.57% of water and 0.5% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: 0.01% of snake venom-like peptide and 80.02% of acetyl hexapeptide;
in the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 0.1%, sodium dihydrogen phosphate: 0.4 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 25 ℃.
In the step S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 25 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
The freeze drying specifically comprises: setting the temperature of a plate layer to be-30 ℃ and the pre-freezing time to be 1 h; after pre-freezing, when the temperature of the rear box reaches-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.6mbar, heating is started; in the primary drying stage, firstly setting the temperature of the plate layer to be 20 ℃ below zero for 8 hours, and then setting the temperature of the plate layer to be 5 ℃ below zero for 1 hour; and in the analysis and drying stage, the temperature of the plate layer is set to be 8 ℃, the duration time is 1h, and the temperature of the plate layer is set to be 20 ℃ again and the duration time is 2 h.
Example 3:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.01% of active polypeptide, 0.01% of sodium hyaluronate, 0.5% of chitosan, 0.1% of protein protective agent, 0.1% of pH buffer agent, 99.27% of water and 0.01% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: nonapeptide-10.001%, tripeptide-10.002%, carnosine 0.007%;
in the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 0.04%, sodium dihydrogen phosphate: 0.06 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 35 ℃.
In the step S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 35 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
The freeze drying specifically comprises: setting the temperature of a plate layer to be-30 ℃ and the pre-freezing time to be 3 h; after pre-freezing, when the temperature of the rear box reaches-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.8mbar, heating is started; in the primary drying stage, firstly setting the temperature of the plate layer to be 10 ℃ below zero for 8 hours, and then setting the temperature of the plate layer to be 5 ℃ for 3 hours; and in the analysis and drying stage, the temperature of the plate layer is set to be 15 ℃ and the duration is 3h, and then the temperature of the plate layer is set to be 40 ℃ and the duration is 5 h.
Example 4:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.4% of active polypeptide, 0.03% of sodium hyaluronate, 1.5% of chitosan, 1% of protein protective agent, 2% of pH buffer, 94.67% of water and 0.4% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: 0.1% of scorpion venom peptide, 0.2% of conopeptide and 0.1% of carnosine;
in the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 1%, sodium dihydrogen phosphate: 1 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 15 ℃.
In the step S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 15 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
Further, the freeze drying specifically comprises: setting the temperature of a plate layer to be 32 ℃ below zero by using a vacuum freeze dryer (the model is GLZY-20B), and pre-freezing for 1.5 h; after pre-freezing, when the temperature of the rear box reaches-42 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.65mbar, heating is started; in the primary drying stage, firstly setting the temperature of the plate layer to be 13 ℃ below zero for 6 hours, and then setting the temperature of the plate layer to be 0 ℃ for 2 hours; and in the analysis and drying stage, the temperature of the plate layer is set to be 9 ℃, the duration time is 1.2 hours, and the temperature of the plate layer is set to be 25 ℃ again and the duration time is 2.5 hours.
Example 5:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.5% of active polypeptide, 0.02% of sodium hyaluronate, 1% of chitosan, 0.4% of protein protective agent, 0.1% of pH buffer, 97.96% of water and 0.02% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: 80.1 percent of acetyl hexapeptide and 0.4 percent of conopeptide.
In the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 0.05%, sodium dihydrogen phosphate: 0.05 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooling to 40 ℃.
In the step S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 40 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
Further, the freeze drying specifically comprises: setting the temperature of a slab layer to be 35 ℃ below zero by using a vacuum freeze dryer (the model is GLZY-20B), and pre-freezing for 2 hours; after pre-freezing, when the temperature of the rear box reaches-45 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.7mbar, heating is started; in the primary drying stage, the temperature of the plate layer is set to be-15 ℃ for 6 hours, and then the temperature of the plate layer is set to be-3 ℃ for 1.5 hours; and in the analysis and drying stage, the temperature of the plate layer is set to be 10 ℃ and the duration time is 2h, and then the temperature of the plate layer is set to be 28 ℃ and the duration time is 3 h.
Example 6:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 0.7% of active polypeptide, 0.8% of sodium hyaluronate, 2% of chitosan, 0.6% of protein protective agent, 1.5% of pH buffer, 94.32% of water and 0.08% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: 0.4 percent of snake venom-like peptide and 0.3 percent of conopeptide.
In the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 1%, sodium dihydrogen phosphate: 0.5 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 15 ℃.
In the step S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 15 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
Further, the freeze drying specifically comprises: setting the temperature of a plate layer to be 36 ℃ below zero by using a vacuum freeze dryer (the model is GLZY-20B), and pre-freezing for 2.5 h; after pre-freezing, when the temperature of the rear box reaches-43 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.7mbar, heating is started; in the primary drying stage, firstly setting the temperature of the plate layer to be-17 ℃ for 7 hours, and then setting the temperature of the plate layer to be 4 ℃ for 2 hours; and in the analysis and drying stage, the temperature of the plate layer is set to be 12 ℃, the duration time is 2.5 hours, and the temperature of the plate layer is set to be 30 ℃ again and the duration time is 2.5 hours.
Example 7:
the liquid (mother liquor) preparation formula of the freeze-dried sponge comprises the following steps: 1% of active polypeptide, 1% of sodium hyaluronate, 3% of chitosan, 1% of protein protective agent, 2% of pH buffer, 91% of water and 1% of recombinant human collagen;
the active polypeptide comprises the following components in percentage by mass: 0.4% of snake venom-like peptide and 0.6% of carnosine.
In the pH buffering agent, disodium hydrogen phosphate and sodium dihydrogen phosphate are in percentage by weight, wherein the weight ratio of the disodium hydrogen phosphate: 0.4%, sodium dihydrogen phosphate: 0.6 percent.
The preparation method of the cosmetic product freeze-dried sponge containing the active polypeptide comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 300 r/min for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding the recombinant human collagen, the sodium hyaluronate and the active polypeptide, and stirring at 300 revolutions per minute until the mixture is completely dissolved to obtain mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
The sterilization in the step S2 is specifically: the mixture was steam sterilized at 121 ℃ for 15 min. Cooled to 10 ℃.
In the step of S2, recombinant human collagen, sodium hyaluronate and active polypeptide are added at 10 ℃.
In the step S3, the freeze drying step includes pre-freezing, vacuum pumping, temperature raising, primary drying, and resolution drying.
Further, the freeze drying specifically comprises: setting the temperature of a plate layer to be 31 ℃ below zero by using a vacuum freeze dryer (the model is GLZY-20B), and pre-freezing for 3 hours; after pre-freezing, when the temperature of the rear box reaches-50 to-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.75mbar, heating is started; in the primary drying stage, the temperature of the plate layer is set to be-10 ℃ for 7.5 hours, and then the temperature of the plate layer is set to be 5 ℃ for 3 hours; and in the analysis and drying stage, the temperature of the plate layer is set to be 15 ℃, the duration time is 2.5 hours, and the temperature of the plate layer is set to be 40 ℃ again and the duration time is 4 hours.
The experimental effects of the present invention will be explained below.
180 volunteers (ages 25 to 55) were selected and randomized into 9 groups. The skin of 20 people in each group is aging-prone skin, the tissue function of the skin is reduced, the skin is dry and rough, the moisture-retaining capacity is reduced, the elasticity is weakened and lackluster, the subcutaneous tissue is reduced and thinned, the skin is loose and drooped, wrinkles are more, pigments are increased, and the like.
Skin tests were performed on physiological saline 1 (control 1), commercial product 2 (control 2), and the lyophilized sponges prepared in examples 1-7 (after the lyophilized sponges were dissolved uniformly in purified water) for 28 consecutive days, twice a day.
The test result shows that the freeze-dried sponge product containing the active polypeptide cosmetic product can improve the elasticity and the tightness of skin to a certain extent, and different skin care and beauty effects can be achieved by adding different active polypeptide types according to different formula proportions.
Claims (10)
1. The freeze-dried sponge is a sponge-like tissue solid product obtained by processing a mother solution prepared according to a formula through a vacuum freeze-drying technology, and the liquid preparation formula of the freeze-dried sponge comprises 0.01-1.0% of active polypeptide, 0.01-1.0% of sodium hyaluronate, 0.01-1.0% of recombinant human collagen, 0.5-3.0% of chitosan, 0.1-1.0% of protein protective agent, 0.1-2.0% of pH buffer and 91.0-99.27% of water by weight.
2. The lyophilized sponge of claim 1 for a cosmetic composition comprising an active polypeptide. The active polypeptide in the liquid preparation formula of the freeze-dried sponge comprises one or more of acetyl hexapeptide-8, snake-like poison peptide, nonapeptide-1, tripeptide-1, melittin, scorpion poison peptide, conopeptide and carnosine.
3. The lyophilized sponge for cosmetic products containing active polypeptide according to claim 1 or 2, wherein the recombinant human collagen in the liquid preparation formulation of the lyophilized sponge is recombinant human collagen iii.
4. The lyophilized sponge for cosmetic preparations containing active polypeptide according to claim 1 or 2, wherein the chitosan in the liquid preparation formulation of the lyophilized sponge is carboxymethyl chitosan.
5. The lyophilized sponge for cosmetic preparations containing active polypeptide according to claim 1 or 2, wherein the protein protectant in the liquid preparation formulation of the lyophilized sponge is mannitol.
6. The lyophilized sponge for cosmetic preparations containing active polypeptide according to claim 1 or 2, wherein the pH buffer comprises disodium hydrogen phosphate and sodium dihydrogen phosphate.
7. A method for preparing the freeze-dried sponge of the cosmetic product containing the active polypeptide according to any one of claims 1 to 6, which comprises the following steps:
s1, adding chitosan, a protein protective agent and a pH buffering agent into water, and stirring at 200-500 rpm for complete dissolution to obtain a mixed solution;
s2, sterilizing and cooling the mixed solution, adding recombinant human collagen, sodium hyaluronate and active polypeptide, and stirring at 200-500 rpm for complete dissolution to obtain a mother solution;
s3, subpackaging the mother solution into penicillin bottles, adding a stopper in half, and freeze-drying in a vacuum freeze-drying machine to obtain the freeze-dried sponge.
8. The method for preparing the lyophilized sponge of the cosmetic product containing the active polypeptide according to claim 7, wherein the temperature of the recombinant human collagen, the sodium hyaluronate and the active polypeptide added in the step of S2 is less than or equal to 40 ℃.
9. The method for preparing the lyophilized sponge for cosmetic products containing active polypeptide as claimed in claim 7, wherein the step of lyophilizing comprises prefreezing, vacuumizing, heating, drying once, and drying by resolution in sequence in step S3.
10. The method for preparing the lyophilized sponge for cosmetic products containing active polypeptide according to claim 7, 8 or 9, wherein the lyophilization is specifically as follows: setting the temperature of a plate layer to be-40 to-30 ℃, and pre-freezing for 1 to 3 hours; after pre-freezing, when the temperature of the rear box reaches-50 to-40 ℃, vacuumizing is started, and when the vacuum degree is reduced to 0.6 to 0.8mbar, heating is started; in the primary drying stage, firstly setting the temperature of a plate layer to be-20 to-10 ℃ for 5 to 8 hours, and then setting the temperature of the plate layer to be-5 to 5 ℃ for 1 to 3 hours; and in the analysis and drying stage, setting the temperature of the plate layer to be 8-15 ℃ and the duration to be 1-3 h, and then setting the temperature of the plate layer to be 20-40 ℃ and continuing for 2-5 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110352307.8A CN112999096A (en) | 2021-03-31 | 2021-03-31 | Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110352307.8A CN112999096A (en) | 2021-03-31 | 2021-03-31 | Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112999096A true CN112999096A (en) | 2021-06-22 |
Family
ID=76387637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110352307.8A Pending CN112999096A (en) | 2021-03-31 | 2021-03-31 | Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112999096A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113749980A (en) * | 2021-10-20 | 2021-12-07 | 康膝生物医疗(深圳)有限公司 | Freeze-dried full-absorption membrane and preparation and use methods thereof |
| CN113876609A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Anti-aging composition containing hydroxypropyl tetrahydropyrane triol and polypeptide protein and application thereof |
| CN114200133A (en) * | 2021-12-20 | 2022-03-18 | 深圳市昭蓝生物科技有限公司 | Anti-extractable nuclear antigen antibody quality control product and preparation method and application thereof |
| CN115177547A (en) * | 2022-07-20 | 2022-10-14 | 天津瑞湃尔生物科技有限公司 | MiRNA freeze-drying protective agent with repairing function and preparation method of freeze-drying balls of miRNA freeze-drying protective agent |
| CN115350113A (en) * | 2022-07-04 | 2022-11-18 | 广州环亚化妆品科技股份有限公司 | Composition containing peptide and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357259A (en) * | 2011-07-28 | 2012-02-22 | 王珊珊 | Bioprotein sponge and preparation method thereof |
| CN104292497A (en) * | 2013-09-06 | 2015-01-21 | 杨树林 | Preparation method of recombinant human collagen bio-sponge |
| CN109431849A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | A kind of polypeptide freeze-dried composition and preparation method thereof with skin activity |
| CN110840775A (en) * | 2019-12-10 | 2020-02-28 | 王洪波 | Anti-wrinkle firming freeze-dried powder and preparation method thereof |
| CN110960443A (en) * | 2019-12-26 | 2020-04-07 | 广州领衔生物科技有限公司 | Composition containing recombinant human collagen, freeze-dried material, preparation method of freeze-dried material and cosmetic |
| CN111228134A (en) * | 2020-03-03 | 2020-06-05 | 广州鸿懿实业发展有限公司 | Snake venom peptide active freeze-dried powder and preparation method thereof |
| CN111346256A (en) * | 2018-12-22 | 2020-06-30 | 江苏昌吉永生物科技股份有限公司 | Freeze-drying forming optimization method of medical hemostatic healing sponge |
| CN112043621A (en) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | Preservative-free polypeptide composition with anti-aging effect |
| CN112120951A (en) * | 2020-09-28 | 2020-12-25 | 广州源肽生物科技有限公司 | Freeze-dried powder containing astaxanthin liposome and polypeptide compound and preparation method thereof |
-
2021
- 2021-03-31 CN CN202110352307.8A patent/CN112999096A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357259A (en) * | 2011-07-28 | 2012-02-22 | 王珊珊 | Bioprotein sponge and preparation method thereof |
| CN104292497A (en) * | 2013-09-06 | 2015-01-21 | 杨树林 | Preparation method of recombinant human collagen bio-sponge |
| CN111346256A (en) * | 2018-12-22 | 2020-06-30 | 江苏昌吉永生物科技股份有限公司 | Freeze-drying forming optimization method of medical hemostatic healing sponge |
| CN109431849A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | A kind of polypeptide freeze-dried composition and preparation method thereof with skin activity |
| CN110840775A (en) * | 2019-12-10 | 2020-02-28 | 王洪波 | Anti-wrinkle firming freeze-dried powder and preparation method thereof |
| CN110960443A (en) * | 2019-12-26 | 2020-04-07 | 广州领衔生物科技有限公司 | Composition containing recombinant human collagen, freeze-dried material, preparation method of freeze-dried material and cosmetic |
| CN111228134A (en) * | 2020-03-03 | 2020-06-05 | 广州鸿懿实业发展有限公司 | Snake venom peptide active freeze-dried powder and preparation method thereof |
| CN112043621A (en) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | Preservative-free polypeptide composition with anti-aging effect |
| CN112120951A (en) * | 2020-09-28 | 2020-12-25 | 广州源肽生物科技有限公司 | Freeze-dried powder containing astaxanthin liposome and polypeptide compound and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113749980A (en) * | 2021-10-20 | 2021-12-07 | 康膝生物医疗(深圳)有限公司 | Freeze-dried full-absorption membrane and preparation and use methods thereof |
| CN113876609A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Anti-aging composition containing hydroxypropyl tetrahydropyrane triol and polypeptide protein and application thereof |
| CN114200133A (en) * | 2021-12-20 | 2022-03-18 | 深圳市昭蓝生物科技有限公司 | Anti-extractable nuclear antigen antibody quality control product and preparation method and application thereof |
| CN114200133B (en) * | 2021-12-20 | 2024-02-27 | 深圳市昭蓝生物科技有限公司 | Anti-extractable nuclear antigen antibody quality control product and preparation method and application thereof |
| CN115350113A (en) * | 2022-07-04 | 2022-11-18 | 广州环亚化妆品科技股份有限公司 | Composition containing peptide and application thereof |
| CN115177547A (en) * | 2022-07-20 | 2022-10-14 | 天津瑞湃尔生物科技有限公司 | MiRNA freeze-drying protective agent with repairing function and preparation method of freeze-drying balls of miRNA freeze-drying protective agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112999096A (en) | Cosmetic product freeze-dried sponge containing active polypeptide and preparation method thereof | |
| EP2525828B1 (en) | Stabilized proteases for use in skin care | |
| CN109431849A (en) | A kind of polypeptide freeze-dried composition and preparation method thereof with skin activity | |
| CN110833514B (en) | Polypeptide freeze-dried powder and application thereof in preparation of anti-aging cosmetics | |
| CN109010186A (en) | A kind of skin care freeze-dried powder and preparation process rich in polypeptide | |
| CN115554187B (en) | Mussel mucoprotein skin repairing emulsion capable of achieving wet and heat sterilization and preparation method thereof | |
| CN110613680A (en) | Preparation method of gel preparation for wound | |
| CN112043621B (en) | Preservative-free polypeptide composition with anti-aging effect | |
| CN115282065B (en) | Freeze-dried powder containing mesenchymal stem cell exosomes and preparation method and application thereof | |
| CN111249163A (en) | Nourishing and repairing freeze-dried powder and preparation method thereof | |
| CN113041391A (en) | Herba centellae-collagen-containing repairing freeze-dried sponge and preparation method thereof | |
| CN111420023B (en) | Complex containing type I collagen and hyaluronic acid, preparation and application | |
| KR20150135425A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails | |
| CN114712406A (en) | Probiotic flora composition with skin aging preventing function | |
| CN111544323A (en) | Composition for skin repair and preparation method and application thereof | |
| CN113797151B (en) | Repairing gel containing mesenchymal stem cell exosomes and preparation method thereof | |
| CN112120951A (en) | Freeze-dried powder containing astaxanthin liposome and polypeptide compound and preparation method thereof | |
| CN113648251A (en) | Skin repairing composition and preparation method thereof | |
| AU2017101409A4 (en) | Cosmetic composition | |
| CN115645301A (en) | Collagen freeze-dried powder preparation method, skin care product and dressing | |
| CN115227597A (en) | Active collagen freeze-dried preparation and preparation method and application thereof | |
| CN115569104A (en) | Hair loss prevention and hair growth composition containing plant extract and application thereof | |
| CN114010763A (en) | Recombinant human acidic fibroblast growth factor gel and preparation method thereof | |
| CN113456571A (en) | PDRN-containing repairing and regenerating composition and preparation method thereof | |
| CN109260099A (en) | A kind of toner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210622 |